What you should know:
1. Phathom will develop and commercialize Takeda’s potassium competitive acid blocker, vonoprazan, in the U.S., Europe and Canada.
2. Frazier led a $90 million financing round supported by several other investors.
3. Phathom then took out a $50 million loan through Silicon Valley Bank to support developmental efforts.
More articles on gastroenterology:
CHI Franciscan to divest ASC, pay $2.5M to settle anticompetitive lawsuit: 5 things to know
Surgery Partners reports $417M in revenue & more — 10 ASC industry notes
As investors favor ASCs & offices, major skilled nursing operator splits segments
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
